


## PHARMACEUTICAL 2020



## Cyclerion Therapeutics Inc. Rank 249 of 362





## PHARMACEUTICAL 2020



## Cyclerion Therapeutics Inc. Rank 249 of 362

The relative strengths and weaknesses of Cyclerion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cyclerion Therapeutics Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 203% points. The greatest weakness of Cyclerion Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 194% points.

The company's Economic Capital Ratio, given in the ranking table, is -307%, being 4.3% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	101,197
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,249
Liabilities, Non-Current	0
Other Assets	73,668
Other Compr. Net Income	-20
Other Expenses	0
Other Liabilities	0
Other Net Income	2,029
Property and Equipment	11,613
Research and Development	95,140
Revenues	4,507
Selling, General and Administrative Expense	34,404

Output Variable	Value in 1000 USD
Assets	186,478
Liabilities	18,249
Expenses	129,544
Stockholders Equity	168,229
Net Income	-123,008
Comprehensive Net Income	-123,018
Economic Capital Ratio	-307%